

Opinion

Justification of the Principles of Emergency Care for Acute Pneumonia

Igor Klepikov*

MD, Professor, Renton, Washington, USA

Abstract

The action of modern emergency care for patients with AP, on the one hand, requires a wait-and-see period, which is unacceptable in cases of rapidly progressing inflammation. On the other hand, it uses methods that do not take into account the features of the disease mechanisms. All this creates conditions for an excess of complications and treatment failures. The accumulated facts on this problem indicate the need to revise the principles of treatment. Consequently, the most important initial step in this direction seems to be the correction of professional views in accordance with the classical provisions of medical science.

Introduction

Emergency care for acute diseases is an important part of medical care, largely determining its further outcome. The rapid development of the process dictates the use of such methods of care that allow slowing down or eliminating the action of the main mechanisms of the disease, preventing its further progression and the development of complications. In acute inflammatory processes, when swelling and tissue infiltration in the lesion site increase, timely and targeted interventions are required to significantly slow these processes and reduce the risk of further spread of the inflammation zone. The latter circumstance is of paramount importance in the case of localization of damage in vital systems, such as, for example, in acute pneumonia (AP).

Recent data on the outcomes of medical care for AP are surprising and puzzling. Against the background of incredible successes and achievements of modern medicine in various fields and areas, one of the oldest topics - the problem of AP - slowly but steadily continues to strengthen its leading position among the causes of morbidity and mortality [1-3]. At the same time, recently the interest of clinicians and researchers has begun to be attracted by a group with a severe course of the disease, who, as a rule, are sent to Intensive Care Units (ICU), and the treatment outcomes are particularly concerning [4,5]. In such situations with aggressive development of the inflammatory process in one of the vital systems of the body, the role of emergency care is of paramount importance. The results of treatment of this category of patients, which

continue to discourage, despite, it would seem, all possible innovations, require a detailed analysis of the principles of formation and application of emergency care. Without such an analysis, it is impossible to hope for achieving stable success.

Discussion

A brief history of the formation of ideas about the nature of AP

The earliest description of AP is attributed to Hippocrates [6], consequently, for most of the time, this disease remained poorly studied and was interpreted as a severe inflammatory process with high mortality. At the same time, one of the fundamental characteristics of this nosology throughout its history was the postulate that AP gets sick, not infected. Practical confirmation of this formulation is reflected in the established sanitary and hygienic traditions regarding this disease, which do not provide for the isolation of patients and compliance with quarantine conditions.

The first major breakthrough in the study of inflammatory processes occurred at the beginning of our era, when Celsus and Galen described five essential signs of this pathology - heat, pain, redness, swelling, and loss of function. In relation to AP, these classic manifestations of inflammatory changes in the lung tissue remained of little use until the 20th century, when the results of such developing disciplines as physiology and pathophysiology began to appear, as well as the emergence of new diagnostic capabilities with the discovery of X-rays [7].

More Information

***Address for Correspondences:** Igor Klepikov, MD, Professor, Renton, Washington, USA, Email: igor.klepikov@yahoo.com


Submitted: April 17, 2025

Approved: April 28, 2025

Published: April 29, 2025

How to cite this article: Klepikov I. Justification of the Principles of Emergency Care for Acute Pneumonia. J Clin Intensive Care Med. 2025; 10(1): 001-005. Available from: <https://dx.doi.org/10.29328/journal.jcicm.1001051>

Copyright license: © 2025 Klepikov I. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



Consequently, the development of microbiology and the results of studies of the etiology of AP, the first results of which were obtained in the second half of the 19th century, outpaced the study of the functional characteristics of this pathology, which played a significant role in choosing the directions for solving this problem. Already at the end of the 19th century, the so-called microbial theory of the origin of diseases appeared, which in turn stimulated the emergence and development of immunology [8].

The noted period of emergency use of the indicated method of serotherapy turned out to be short-lived, since all these initiatives took place literally on the eve of the appearance of antibiotics, and soon after the beginning of their use and the first results, the relevance of the task began to disappear. Patients with AP began to be considered as patients who did not need the emergency support that had been carried out during the previous decade, and the attitude to this problem itself acquired features of calming and stress relief [8].

The erroneousness of such an assessment began to manifest itself soon after the beginning of widespread antibiotic therapy, since the qualitative characteristics of these drugs were known even before the beginning of their practical use, and its essence indicated the discrepancy between the possibilities of this therapy and the role that was assigned to it in practice. In addition, before the beginning of the practical implementation of this antimicrobial care, it was known that its effectiveness could not be long-term [9,10].

Consequences of a long period of antibiotic therapy

The initial confidence in the rapid effects and convenience of antibiotics outweighed efforts toward strict control over the targeted use of these drugs and a balanced assessment of the changes that began to appear and gradually increase. Transformations in microflora, including changes in AP pathogens and the emergence of microbial resistance did not find any other solution than the accelerated development and release of new generations of these drugs in the first decades [11]. Confidence in antibiotics as the primary treatment for inflammatory diseases continued to grow, and the prescription of this therapy to many patients was of the nature of “antibiotics alone.” This assessment of antibiotic therapy continued to grow and dominate professional views, despite the fact that these drugs are capable of acting only against certain types of pathogens, but do not have a direct effect on the mechanisms of inflammation.

It is now known that the initial idyll of antibiotic use could not long be maintained in the role it played in the early years. Over time, the number and diversity of resistant microflora increased, and early attempts at targeted antibiotic therapy were unsuccessful. The number of AP cases requiring additional and supportive therapy gradually increased. The etiology of AP became increasingly resistant to antibiotic therapy, and viruses turned into a key problem of the disease

[12-14]. In recent years, the number of patients with AP in whom the pathogen remains unidentified has consistently exceeded half of the cases [15]. Consequently, by this time, antibiotics, paradoxically, despite all the inconsistencies and contradictions, have firmly entered the professional consciousness as a kind of panacea, without which modern medicine no longer sees other ways to treat patients with AP.

Currently, antibiotics are responsible for all the main tasks that need to be solved to achieve success in the treatment of patients with AP. These drugs are still considered by most clinicians as the main methods of treatment. Many specialists continue to consider this therapy not only as the primary approach but also as the sole therapeutic option. At the same time, this therapy simultaneously continues to play the role of first emergency care for this group of patients. Since the effect of these drugs cannot be manifested by an immediate change in the measured parameters of the patient's condition, standard and widespread recommendations suggest a waiting period of up to 48 hours - 72 hours [16,17].

Infusion therapy and AP

Such a wait-and-see period in patients with AP cannot be completely passive in all observations. Many of them require additional or auxiliary care. According to the dominant concept of the disease, in which the pathogen is considered as its main cause, such supportive therapy is aimed at eliminating the consequences of the infectious factor and today has a single standard for all inflammatory processes, regardless of localization.

The most common method of supporting patients with inflammatory diseases is intravenous infusions of solutions, which in most observations begin from the moment of hospitalization of patients and are considered as a preventive measure for possible septic circulatory disorders. Subsequently, in this case, the fact that the circulatory systems of the small and large circles of blood circulation have a common interdependence and regulation, remaining with directly opposite blood flow indicators is not taken into account. In addition, it is in patients with AP that any intravenous infusion first reaches the inflammation zone with the increasing processes of edema and tissue infiltration at this time.

Unlike inflammatory processes within the systemic circulation, damage to lung tissue in severe cases of the disease is accompanied by generalized spasm of the pulmonary vessels, which causes signs of their overload [18-20]. The author of these lines has well felt and proven from his own experience what unpleasant surprises can await both the patient with AP and his attending staff in the event of early infusion therapy [18]. In this regard, the results of treatment of patients with AP, reflecting the state of medical care in modern medicine, are a natural consequence of the existing principles of emergency care for this category. As a result of

the ineffectiveness of the initiated treatment, the deterioration of the condition of up to 25% of patients with AP admitted to general departments requires their transfer to the ICU already in the first 2 days [21,22]. The overall results show that the main problem is represented by patients with a severe course of the disease, for whom timely and adequate emergency care is of fundamental importance [1-3,22,23].

Critique of current emergency care approaches for acute pneumonia

It is surprising and difficult to explain from a logical and critical standpoint of the main facts related to the problem of AP that the search for its solution in modern conditions obsessively and stubbornly continues to focus on the diagnosis of pathogens and the search for the most optimal antibiotics [14,16,17,24,25]. This perception of approaches to key disease characteristics that today relate to the foundations of the problem of AP creates the impression that there were no 80 years of antibiotic use and everything is starting "from scratch", and the leading causative agent of the disease is still pneumococcus.

But everyone is well aware of the data on the fundamental changes that have occurred in the etiology of the disease during this period. Such changes include a radical shake-up of the list of pathogens, in which viruses began to occupy a significant place [12-14]. At the same time, the percentage of AP observations is growing, already exceeding half of all cases in which the pathogen cannot be identified, and the question of the exact choice of etiologic agents remains open [15,17,26].

All the initiatives described in the above publications do not bring the expected shifts in results, but the general conclusion is a persistent assertion about the need for further research in this direction. Such conclusions would be justified if methodological flaws had occurred during the research process, but there are no such indications, and the fanatical commitment to the previous concept of the disease remains unshakable.

In addition to these firmly established misconceptions about the nature of the disease, which have the character of unshakable clichés, we should add a clearly exaggerated assessment of resistant microflora. This phenomenon, the development of which was predicted even before the beginning of the clinical use of antibiotics and accompanied this therapy with its appearance and development throughout the entire period, has recently begun to attract attention only because the effectiveness of the main therapeutic hope - antibiotics - has significantly decreased. Without real proposals for a way out of this situation, the resistance of AP pathogens began to be indicated as the reason for the lack of success in the treatment of these patients.

A number of facts indicate that the frightening assessment of resistant microflora, which has now become the main

symbol of lively discussions and one of the medical sections with suddenly increased attention and interest in it, is clearly and significantly exaggerated. Firstly, resistant strains have become familiar representatives of normal microflora, being symbionts of the microbiota of healthy people. For example, the prevalence of MRSA in the body of various categories of the population and professions fluctuates from 2% to 10%, without causing any problems to its carriers [27-31]. In the composition of the surrounding microflora, MRSA can make up to 35%, cephalosporin-resistant *E. coli* - up to 42% [32], resistant strains of pneumococcus - up to 20% [33,34].

Secondly, at present, in the majority of patients with AP, as already noted, the pathogens remain unidentified, and the bacterial etiology of the disease accounts for less than half of the cases, where resistant strains represent an insignificant group [14]. Such a number of observations with resistant pathogens of inflammation cannot in any way serve as an explanation for the significantly greater number of failures that continue to occur in "simple" forms of the disease.

Thirdly, resistant strains of AP pathogens can pose a serious problem for the treatment of such patients only if etiologic drugs continue to be considered the main means of providing medical care. This is exactly what is happening now, when antibiotics, despite the change in the etiology of the disease and the facts of direct ignoring of the pathogenetic side of the process, continue to determine the strategy for solving the entire problem.

Fourthly, modern medicine, continuing to focus on the leading role of the AP pathogen and hoping for the success of targeted antimicrobial therapy, has been trying for many years to find ways to differentially diagnose AP depending on the type of bacterial pathogen. Not only have repeated attempts at such efforts been in vain, but the desire to separate the bacterial and viral forms of the disease has also been unsuccessful [35-37]. It would seem that such results clearly show that the causative agent of the inflammatory process does not have a specific effect on the manifestations of the disease, which retains its main features regardless of etiology. Yet, modern reality shows that all this rich experience, indicating the need to finally pay attention to the integral features of pathogenesis, has remained without critical analysis, and attempts to separate AP by the type of pathogen continue [24,38].

Finally, the persistent and narrow focus on reviving the former efficacy of antibiotics that would continue to provide emergency assistance gives rise to ideas for developing new types of antimicrobial drugs, and such initiatives, supported by WHO experts, are acquiring a global character [39]. In actual fact, this reflects the continued pursuit of therapeutic directions that contributed to the emergence of severe side effects, which now require correction. In the context of significant changes in the foundations of the development

of AP that have occurred during the period of antibiotic use, without a comprehensive analytical assessment of the observed transformations, continuing to blindly demonstrate an unwavering commitment to continuing and improving this direction is a very rash step. And here, plans to create completely new versions of such drugs at the level of molecules, nano- and genetic technologies are of particular concern [40,41]. The potential consequences of implementing such plans remain difficult to predict, pursuing only the achievement of an antimicrobial effect, without imagining the natural protective reactions and their consequences.

Hence, emergency care for patients with AP remains focused on the expected success of etiotropic therapy, which requires, especially in conditions of aggressive development of the process, an unacceptably long wait. The initial stage of treatment involves monitoring of key vital indicators of vital functions of the body. At the same time, the conducted studies of the pathogenesis of the disease and attempts to apply the obtained results are based on the study of cellular and molecular deviations that form a virtual representation of the current process, but do not provide tangible practical advantages. Parallel appointment of auxiliary and additional means of assistance is used without taking into account the standard mechanisms of development of the disease panorama. Ultimately, patients with AP find themselves without real and effective emergency care, demonstrating a natural loss of timely opportunities for success.

The above picture of modern approaches to solving the problem of AP allows us to note that the main reason for the existing misconceptions in this matter is the negative didactic role of antibiotics in the formation of a professional worldview about the nature of this disease. In this regard, it seems completely unnecessary in this context to provide a description of already tested pathogenetic methods of providing first aid with objective evidence of their real effectiveness [18]. Such a description without a preliminary and radical revision of the foundations of the disease and a rethinking of all the accumulated facts in the light of the classical canons of medical science may turn out to be a completely ineffective presentation. Nevertheless, such a correction of views on the problem under discussion is an inevitable step, and its implementation today requires the same urgency as the use of the missing pathogenetic emergency care.

Conclusion

The current situation in managing patients with AP indicates that this category actually does not have emergency and effective emergency care. The approaches used today to this most important section of treatment have a narrowly targeted symptomatic effect and continue to be dictated by established traditions and impressions. The facts accumulated over the past decades convincingly refute the modern system of views on the problem under discussion. For the success of the necessary correction in this area, it is necessary to begin

the revision not with a change in treatment methods, but with a revision of our own ideas about the nature and mechanisms of this disease. New pathogenetically informed principles for providing emergency care to these patients will naturally emerge, which will move the problem from a dead point.

References

1. Silva PGOE, Batista Filho LAC, Flores IP, Vilins e Silva V, Maciel AT, Medeiros LS, et al. Community-acquired pneumonia: Epidemiology, diagnosis, prognostic severity scales, and new therapeutic options. *Medwave*. 2023;23(11):e2719. Available from: <https://doi.org/10.5867/medwave.2023.11.2719>
2. File TM, Ramirez JA. Community-Acquired Pneumonia. *N Engl J Med*. 2023;389:632–41. Available from: <https://doi.org/10.1056/nejmcp2303286>
3. Cavallazzi R, Ramirez JA. Definition, Epidemiology, and Pathogenesis of Severe Community-Acquired Pneumonia. *Semin Respir Crit Care Med*. 2024;45(2):143–57. Available from: <https://doi.org/10.1055/s-0044-1779016>
4. Greco M, De Corte T, Ercole A, Antonelli M, Azoulay E, Citerio G, et al. Clinical and organizational factors associated with mortality during the peak of first COVID-19 wave: the global UNITE-COVID study. *Intensive Care Med*. 2022;48:690–705. Available from: <https://doi.org/10.1007/s00134-022-06705-1>
5. Cheng GS, Crothers K, Aliberti S, Bergeron A, Boeckh M, Chien JW, et al. Immunocompromised Host Pneumonia: Definitions and Diagnostic Criteria: An Official American Thoracic Society Workshop Report. *Ann Am Thorac Soc*. 2023;20:341–53. Available from: <https://doi.org/10.1513/annalsats.202212-1019st>
6. Feigin R. Textbook of Pediatric Infectious Diseases. 5th ed. Philadelphia: W.B. Saunders. 2004;299.
7. Novelline R. Squire's Fundamentals of Radiology. 5th ed. Cambridge (MA): Harvard University Press; 1997. Available from: https://www.hup.harvard.edu/file/feeds/PDF/9780674057951_sample.pdf
8. Podolsky SH. The changing fate of pneumonia as a public health concern in 20th-century America and beyond. *Am J Public Health*. 2005;95(12):2144–54. Available from: <https://doi.org/10.2105/ajph.2004.048397>
9. Abraham EP, Chain E. An enzyme from bacteria able to destroy penicillin. 1940. *Rev Infect Dis*. 1988;10(4):677–8. Available from: <https://pubmed.ncbi.nlm.nih.gov/3055168/>
10. Rammelkamp T. Resistance of *Staphylococcus aureus* to the action of penicillin. *Exp Biol Med*. 1942;51:386–9. Available from: <https://doi.org/10.3181/00379727-51-13986>
11. Aminov RI. A brief history of the antibiotic era: lessons learned and challenges for the future. *Front Microbiol*. 2010;1:134. Available from: <https://doi.org/10.3389/fmicb.2010.00134>
12. Jain S, Self WH, Wunderink RG, Fakhran S, Balk R, Bramley AM, et al. Community-acquired pneumonia requiring hospitalization among U.S. adults. *N Engl J Med*. 2015;373:415–27. Available from: <https://doi.org/10.1056/nejmoa1500245>
13. Shorr AF, Zilberberg MD, Micek ST, Kollef MH. Viruses are prevalent in non-ventilated hospital-acquired pneumonia. *Respir Med*. 2017;122:76–80. Available from: <https://doi.org/10.1016/j.rmed.2016.11.023>
14. Palomeque A, Cilloniz C, Soler-Comas A, Canseco-Ribas J, Rovira-Ribalta N, Motos A, et al. A review of the value of point-of-care testing for community-acquired pneumonia. *Expert Rev Mol Diagn*. 2024;1–14. Available from: <https://doi.org/10.1080/14737159.2024.2391027>
15. Shoar S, Musher DM. Etiology of community-acquired pneumonia in adults: a systematic review. *Pneumonia*. 2020;12:11. Available from: <https://doi.org/10.1186/s41479-020-00074-3>
16. Metlay JP, Waterer GW, Long AC, et al. Diagnosis and Treatment of Adults with Community-Acquired Pneumonia. An Official

- Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. *Am J Respir Crit Care Med*. 2019;200(7):e45–67. Available from: <https://doi.org/10.1164/rccm.201908-1581st>
17. Martin-Loeches I, Torres A, Nagavci B, Aliberti S, Antonelli M, Bassetti M, et al. ERS/ESICM/ESCMID/ALAT guidelines for the management of severe community-acquired pneumonia. *Intensive Care Med*. 2023;49:615–32. Available from: <https://doi.org/10.1007/s00134-023-07033-8>
 18. Klepikov I. The Didactics of Acute Lung Inflammation. Newcastle upon Tyne (UK): Cambridge Scholars Publishing; 2022. 320 p. ISBN: 1-5275-8810-6. ISBN13: 978-1-5275-8810-3. Available from: <https://doi.org/10.58489/2836-2411/007>
 19. Thillai M, Patvardhan C, Swietlik EM, McLellan T, De Backer J, Lanclus M, et al. Functional respiratory imaging identifies redistribution of pulmonary blood flow in patients with COVID-19. *Thorax*. 2021;76:182–4. Available from: <https://doi.org/10.1136/thoraxjnl-2020-215395>
 20. Dierckx W, De Backer W, Links M, De Meyer Y, Ides K, et al. CT-derived measurements of pulmonary blood volume in small vessels and the need for supplemental oxygen in COVID-19 patients. *J Appl Physiol*. 2022;133(6):1295–9. Available from: <https://doi.org/10.1152/japophysiol.00458.2022>
 21. Boëlle P-Y, Delory T, Maynadier X, Janssen C, Piarroux R, Pichenot M, et al. Trajectories of hospitalization in COVID-19 patients: An observational study in France. *J Clin Med*. 2020;9:3148. Available from: <https://doi.org/10.3390/jcm9103148>
 22. Cavallazzi R, Furmanek S, Arnold FW, Beavin LA, Wunderink RG, Niederman MS, et al. The burden of community-acquired pneumonia requiring admission to ICU in the United States. *Chest*. 2020;158:1008–16. Available from: <https://doi.org/10.1016/j.chest.2020.03.051>
 23. Laporte L, Hermetet C, Jouan Y, Gaborit C, Rouve E, Shea KM, et al. Ten-year trends in intensive care admissions for respiratory infections in the elderly. *Ann Intensive Care*. 2018;8:84. Available from: <https://doi.org/10.1186/s13613-018-0430-6>
 24. Pan D, Nielsen E, Chung S, Niederman MS. Management of pneumonia in the critically ill. *Minerva Med*. 2023;114:667–82. Available from: <https://doi.org/10.23736/s0026-4806.22.08467-1>
 25. Zhang JH, Chou SF, Wang PH, Yang CJ, Lai YH, Chang MY, et al. Optimizing patient outcomes in severe pneumonia: the role of multiplex PCR in the treatment of critically ill patients. *Front Med (Lausanne)*. 2024;11:1391641. Available from: <https://doi.org/10.3389/fmed.2024.1391641>
 26. Rabin EE, Walter JM, Wunderink RG, Qi C, Pickens CI. Clinical significance of culture-negative, PCR-positive bronchoalveolar lavage results in severe pneumonia. *ERJ Open Res*. 2023;9(6):00343–2023. Available from: <https://doi.org/10.1183/23120541.00343-2023>
 27. Millar MR, Walsh TR, Linton CJ, Zhang S, Leeming JP, Bennett PM. The ALSPAC Study Team. Carriage of antibiotic-resistant bacteria by healthy children. *J Antimicrob Chemother*. 2001;47(5):605–10. Available from: <https://doi.org/10.1093/jac/47.5.605>
 28. Centers for Disease Control and Prevention (CDC). Methicillin-resistant *Staphylococcus aureus* (MRSA): Healthcare Settings. 2023. Available from: <https://www.cdc.gov/mrsa/about/index.html>
 29. Albrich WC, Harbarth S. Health-care workers: Source, vector, or victim of MRSA? *Lancet Infect Dis*. 2008;8:289–301. Available from: [https://doi.org/10.1016/s1473-3099\(08\)70097-5](https://doi.org/10.1016/s1473-3099(08)70097-5)
 30. Aubry-Damon H, Grenet K, Ndiaye-Sall P, Che D, Corderio E, Bougnoux M, et al. Antimicrobial resistance in commensal flora of pig farmers. *Emerg Infect Dis*. 2004;10(5):873–9. Available from: <https://doi.org/10.3201/eid1005.030735>
 31. Graveland H, Wagenaar JA, Heesterbeek H, Mevius D, van Duikeren E, Heederik D. Methicillin-resistant *Staphylococcus aureus* ST398 in veal calf farming: Human MRSA carriage related with animal antimicrobial usage and farm hygiene. *PLoS One*. 2010;5(6):e10990. Available from: <https://doi.org/10.1371/journal.pone.0010990>
 32. World Health Organization. Antimicrobial resistance. 2023. Available from: <https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance>
 33. Lynch JP III, Zhanel GG. *Streptococcus pneumoniae*: does antimicrobial resistance matter? *Semin Respir Crit Care Med*. 2009;30(2):210–38. Available from: <https://doi.org/10.1055/s-0029-1202939>
 34. Linares J, Ardanuy C, Pallares R, Fenoll A. Changes in antimicrobial resistance, serotypes and genotypes in *Streptococcus pneumoniae* over a 30-year period. *Clin Microbiol Infect*. 2010;16(5):402–10. Available from: <https://doi.org/10.1111/j.1469-0691.2010.03182.x>
 35. Heneghan C, Plueddemann A, Mahtani KR. Differentiating viral from bacterial pneumonia. Oxford: Centre for Evidence-Based Medicine, University of Oxford; 2020. Available from: <https://www.cebm.net/covid-19/differentiating-viral-from-bacterial-pneumonia>
 36. Kamat IS, Ramachandran V, Eswaran H, Guffey D, Master DM. Procalcitonin to distinguish viral from bacterial pneumonia: a systematic review and meta-analysis. *Clin Infect Dis*. 2020;70(3):538–42. Available from: <https://doi.org/10.1093/cid/ciz545>
 37. Lhommet C, Garot D, Grammatico-Guillon L, Jourdainaud C, Asfar P, Faisy C, et al. Predicting the microbial cause of community-acquired pneumonia: can physicians or a data-driven method differentiate viral from bacterial pneumonia at patient presentation? *BMC Pulm Med*. 2020;20:62. Available from: <https://doi.org/10.1186/s12890-020-1089-y>
 38. Schuurman AR, Reijnders TDY, van Engelen TSR, Léopold V, de Brabander J, van Linge C, et al. The host response in different aetiologies of community-acquired pneumonia. *EBioMedicine*. 2022;81:104082. Available from: <https://doi.org/10.1016/j.ebiom.2022.104082>
 39. World Health Organization. Antimicrobial resistance. 2021. Available from: <https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance>
 40. Serwecińska L. Antimicrobials and antibiotic-resistant bacteria: A risk to the environment and to public health. *Water*. 2020;12(12):3313. Available from: <https://doi.org/10.3390/w12123313>
 41. Hsu J. AI discovers new class of antibiotics to kill resistant bacteria. *New Sci*. 2024;261(3472):12. Available from: [https://doi.org/10.1016/S0262-4079\(24\)00011-3](https://doi.org/10.1016/S0262-4079(24)00011-3)